Pharmaceuticals

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

EUIPO figures reveal that trademark infringement is an expensive business in Denmark

By AWA | Posted on January 20, 2020

The 2019 Status Report on IPR Infringement from the European Union Intellectual Property Office (EUIPO) reveals that the annual sales lost due to counterfeiting in Denmark amount to €828 million. This represents 4.2% of the total sales in the 11 sectors covered by the report, which included cosmetics and personal care, clothing, footwear and accessories and pharmaceuticals....

Tags: cosmetics, counterfeits, Denmark, EUIPO, Infringement, personal care, Pharmaceuticals, trademarks

Poverty versus patenting in India – round two

By Jeanette Jakobsson | Posted on November 22, 2012

Earlier this year the first compulsory license, regarding the anti-cancer drug Sorafenib, was granted in India. (See previous blog post.) The compulsory license was granted inter alia on the ground that the patented invention was not available to the public at a reasonable affordable price. The battle towards affordable medicaments in India continues. In a...

Tags: compulsory license, drug patents, India, Pharmaceuticals

Court of Justice of the EU confirms zero or negative duration for SPCs

By Sidsel Hauge | Posted on December 13, 2011

On 8 December 2011, the Court of Justice of the European Union (CJEU) issued its judgment in case C-125/10 (“Merck”). This case concerns the duration of a Supplementary Protection Certificate (SPC) according to Article 13 of the SPC Regulation EG/469/2009. Summary of the case Merck applied for a SPC for the product Sitaglipin under conditions...

Tags: CJ, ECJ, Patent, Pharmaceuticals, SPC

Counterfeit pharmaceuticals case settled without main hearing

By AWA | Posted on June 1, 2011

In April 2010 Eli Lilly and Company (“Lilly”), the manufacturer of the erectile dysfunction pharmaceutical Cialis, was informed that the Swedish customs had ceased a consignment of products marked and/or shaped in such a way that it was suspected to infringe the intellectual property rights of Lilly. The consignment was addressed to an individual, herein...

Tags: EEA, Infringement, Pharmaceuticals

Recent contributors

Laura Stravinskaite

Laura Stravinskaite

Senior Associate, Attorney at Law

Ai-Leen Lim

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Ashley Zhao

Ashley Zhao

Partner, Attorney at Law, Business Area Manager

Troels Peter Rørdam

Troels Peter Rørdam

Senior Counsel, European Patent Attorney

Mikkel Roed Trier

Mikkel Roed Trier

Partner, European Patent Attorney, UPC Representative, Business Area Manager